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Recent outbreaks with carbapenem-resistant Enterobacteriaceae (CRE) in patients who have undergone 
endoscopic retrograde cholangiopancreatography (ERCP) have raised concerns of whether current en-
doscope reprocessing guidelines are adequate to ensure a patient-safe endoscope. Unlike previous outbreaks, 
these CRE outbreaks occurred even though manufacturer’s instructions and professional guidelines were 
followed correctly. This article reviews why outbreaks associated with endoscopes continue to occur; what 
alternatives exist that might improve the margin of safety associated with duodenoscope reprocessing; 
and how to prevent future outbreaks associated with ERCP procedures. The advantages and disadvan-
tages for the proposed enhancements for reprocessing duodenoscopes are reviewed as well as future 
strategies to prevent GI endoscope-related outbreaks.
In the last 2 years, multiple reports of outbreaks have led the
Food and Drug Administration (FDA), Centers for Disease Control
and Prevention (CDC), and national news to raise awareness among
the public and health care professionals that the complex design
of duodenoscopes (used primarily for endoscopic retrograde
cholangiopancreatography [ERCP]) may impede effective
reprocessing.1,2 Several recent publications have associated
multidrug-resistant (MDR) bacterial infections, especially those
caused by carbapenem-resistant Enterobacteriaceae (CRE), in pa-
tients who have undergone ERCPwith reprocessed duodenoscopes.3-5
Unlike other endoscope outbreaks, these recent outbreaks oc-
curred even when the manufacturer’s instructions and professional
guidelines were followed correctly.3,4 The purpose of this article,
which is adapted from recent publications,6,7 is 3-fold: (1) why do
outbreaks associated with endoscopes continue to occur; (2) what
alternatives exist today that might improve the safety margin as-
sociated with duodenoscope reprocessing; and (3) how to prevent
future outbreaks associated with ERCP endoscopes and other gas-
trointestinal (GI) endoscopes.6
The key concern raised by these outbreaks is that current re-
processing guidelines are not adequate to ensure a patient-safe GI
endoscope (one devoid of potential pathogens) because the margin
of safety associatedwith reprocessing endoscopes is minimal or non-
existent. There are 2 (and possibly 3) reasons for this reprocessing
failure and why outbreaks continue to occur. First, studies have
shown that the internal channel of GI endoscopes, including
duodenoscopes, may contain 107-10 (7-10 log10) enteric
microorganisms.8,9 Investigations have demonstrated that the clean-
ing step in endoscope reprocessing results in a 2-6 log10 reduction
of microbes, and the high-level disinfection (HLD) step results in
another 4-6 log10 reduction of mycobacteria, for a total 6-12 log10
reduction of microbes.8-10 Therefore, the margin of safety associ-
ated with cleaning and HLD of GI endoscopes is minimal or
nonexistent (level of contamination: 4 log10 [maximum contami-
nation, minimal cleaning/HLD] to -5 log10 [minimum contamination,
maximum cleaning/HLD]). Therefore, any deviation from proper re-
processing (eg, crevices associated with the elevator channel) could
lead to failure to eliminate contamination, with a possibility of sub-
sequent patient-to-patient transmission. This low (or nonexistent)
margin of safety associated with endoscope reprocessing com-
pares with the 17 log10 margin of safety associated with cleaning
and sterilization of surgical instruments (ie, 12 log10 reduction
via sterilization and at least a net 5 log10 reduction based on
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microbial load on surgical instruments [2 log10] and microbial re-
duction via a washer disinfector [7 log10]).
Second, GI endoscopes not only have a heavy microbial con-
tamination (107-1010 bacteria), but they are complex, with long,
narrow channels and right angle turns and have difficult to clean
and disinfect components (eg, elevator channel). The elevator channel
in duodenoscopes is unique to side-viewing endoscopes. It has a
separate channel and provides orientation of catheters, guidewires,
and accessories into the endoscopic visual field.6,7 This channel is
complex in design and has crevices that are difficult to access with
a cleaning brush and may impede effective reprocessing.2 Based on
this and other recent studies, it is likely that MDR pathogens are
acting as a marker or indicator organism for ineffective reprocess-
ing of the complex design of duodenoscopes, which is an infectious
risk to patients. It is unclear if echoendoscopes that have an ele-
vator channel for the same reasons as ERCP scopes (directing
accessories) pose the same disinfection challenges and similar in-
fectious risks because these scopes are used to violate otherwise
sterile spaces when used to obtain diagnostic samples and for ther-
apeutic interventions.
The third issue that could impact endoscope reprocessing failure
and continued endoscope-related outbreaks is the development of a
biofilm.11 Biofilms aremultilayered bacteria plus exopolysaccharides
that cement cells to surfaces. They develop in a wet environment. If
reprocessing is performed promptly after use and the endoscope is
dry, the opportunity for biofilm formation is minimal.12 It is unclear
if biofilms contribute to failure of endoscope reprocessing.
Given the heavy microbial contamination (107-1010) and endo-
scope components that are difficult to clean and disinfectant (eg,
elevator channel), are current endoscope reprocessing guidelines
adequate to ensure a GI endoscope devoid of potential patho-
gens? To examine this question we briefly review the current
knowledge on endoscope reprocessing and then offer recommen-
dations. First, endoscopes are semicritical items that require at least
HLD.13,14 Because flexible GI endoscopes are currently heat labile,
only HLD with FDA-cleared high-level disinfectants or low-
temperature sterilization technologies (LTSTs) are possible.13
Unfortunately, at present, no solution exists that has been proven
to eliminate the risk of microbial contamination associated with
duodenoscopes. For example, there is no LTST that achieves a ste-
rility assurance level (SAL) of 10-6 for GI endoscopes such as
duodenoscopes. Second, there have been more health care–
associated outbreaks linked to contaminated endoscopes than to
any other reusable medical device.13,15 However, until recently, these
outbreaks have been traced to deficient practices, such as inade-
quate cleaning, inappropriate disinfection (eg, failure to perfuse all
channels), and damaged endoscopes or flaws in the design of en-
doscopes (eg, duodenoscope elevator channel) or automated
endoscope reprocessors.13,15 Reprocessing failures have led to patient
notifications and bloodborne pathogen testing in dozens of
instances.16 Third, evidence-based endoscope reprocessing guide-
lines have been prepared by professional organizations and the CDC,
and past data suggested that rigorous adherence to these guide-
lines would result in a patient-safe endoscope.13,14 Unfortunately,
there are also data that demonstrate that all of the steps associ-
ated with manual endoscope reprocessing are rarely performed and
some essential steps (eg, brushing all endoscope channels and com-
ponents) are uncommonly performed.17 Endoscope reprocessing was
improvedwith the use of automated endoscope reprocessors because
most steps were automated.17 Fourth, endemic transmission of in-
fections associatedwith GI endoscopesmay go unrecognized because
of inadequate surveillance of outpatient procedures, the long lag
time between colonization and infection, and a low frequency of
infection. Additionally, the risk for some procedures might be lower
than others (eg, colonoscopy vs ERCP, where normally sterile areas
are contaminated in the latter). In the outbreak reported byWendorf
et al, it was the presence of an unusual pathogen (AmpC-producing
Escherichia coli) that resulted in an investigation and recognition that
duodenoscopes were the source of the outbreak.3
What shouldwedonow?Unfortunately, there is currentlynosingle,
simple, and proven technology or prevention strategy that hospitals
can use to guarantee patient safety. Of course, we must continue to
emphasize the enforcement of evidence-based practices, including
equipment maintenance and routine audits, with at least yearly
competency testing of reprocessing staff.13,14 All reprocessing per-
sonnel must be knowledgeable and thoroughly trained on the
reprocessing instructions for duodenoscopes. This includes the new
recommendations to use a small bristle cleaning brush and for ad-
ditional flushing and cleaning steps of the elevator channel
(http://medical.olympusamerica.com/sites/default/files/pdf/150326
_TJF-Q180V_Customer_letter.pdf). Although these steps were de-
scribed as validated, nopublic data are available on the ability of these
newcleaning recommendations to yield anERCP scopedevoid of bac-
teria. However, we must do more or additional outbreaks will likely
continue. We must obtain additional information on the frequency
and level of microbial contamination of endoscopes that have been
cleaned and high-level disinfected with strict adherence to current
guidelines. If endoscopes are found to be contaminated with poten-
tial pathogens (eg, enteric gram-negative bacilli), the clinical impact
of such contamination needs to be quantified. In addition, based on
the study by Wendorf et al and others,3-5 it would be reasonable to
considerperiodicmicrobiologicsurveillanceofduodenoscopes toassess
microbial contamination as a component of a prevention strategy;
however, culture results are delayed 2-3 days, and there are many
questions related to microbiologic surveillance.1 These include the
following: what cutoff should be used to define proper disinfection
(eg, 0 pathogens or ahigher number, such as <10 colony formingunits
[CFU] of enteric pathogens per channel)?; should there be a sepa-
ratecutoffbasedonrelativelynonvirulentpathogens, suchascoagulase-
negative Staphylococcus?; what sampling scheme should be used to
evaluate GI endoscopes (eg, all scopes or a sample of endoscopes)?;
if a hospital cultures 2 endoscopes of 10 and 1 endoscope is positive,
do they reprocess all 10 endoscopes because 50% of the sampled en-
doscopes are positive?; if a hospital does periodic microbiologic
culturing and 20% of sampled endoscopes are positive, what actions
should an endoscopy unit undertake (eg, patient notification with
an offer of bloodborne pathogen testing, stool examination for CRE,
ethylene oxide [ETO] sterilization of positive endoscopes, or HLD fol-
lowed by ETO sterilization of all duodenoscopes)?; has the staff been
trained on culturing the duodenoscope channels and the elevator
channel?; and is the trigger for further action based on the level of
contamination or the frequency of contamination (ie, percent of en-
doscopescontaminated)or infection?6,7 Inaddition, if ahospitaldecides
to culture all endoscopes andquarantine endoscopes for 48-72hours
while awaiting culture results before using the scope, itmust be rec-
ognized that the sensitivity of culturing the elevator channel of the
scope or the scope is unknown (ie, how many microbes must con-
taminate the endoscope to yield a positive culture?). Until there are
evidence-based guidelines, individual hospitals should base their de-
cisions on best available information (eg, clinical risk) and what is
feasible for theirhospital.
Real-time, monitoring methods need to be developed and vali-
dated to assess the effectiveness of cleaning and HLD and the risk
of infection. Adenosine triphosphate (ATP) detection of effluent has
been offered as a monitoring tool18,19 for assessing cleaning because
it detects organic residuals. Although ATP may be used to assess en-
doscope cleaning, it is neither a good indicator of microbial
contamination nor validated as a method to assess the risk for
patient-to-patient transmission. A validation study of ATP used to
audit cleaning of flexible endoscope channels used a benchmark for
clean (<200 relative light units), which equated to <4 log10 CFU/
cm2 (or 104 CFU/cm2)18 or approximately 106 CFU per endoscope
because the surface area of an endoscope channel is >100 cm2. There-
fore, an endoscope assessed as clean by ATP could still have a
significant microbial load (eg, 106).
In regard to the future, we predict that we will continue to see
outbreaks associated with ERCP endoscopes and GI endoscopes if
we do only the enhanced strategies previously described. One so-
lution to this infection prevention challenge would be to develop
new endoscope reprocessing technologies that reliably result in ster-
ilization of duodenoscopes and other GI endoscopes via an FDA-
cleared sterilization process that achieves an SAL of 10−6. This SAL
results in a 12 log10 reduction of microorganisms compared with
the 6 log10 reduction for HLD. This 6 log10 reduction difference is
the margin of safety that will ensure endoscopes are devoid of mi-
crobial contamination. This can be done by optimizing current LTST
(eg, hydrogen peroxide gas plasma, ETO, vaporized hydrogen per-
oxide) or evaluating new sterilization technologies (eg, ozone plus
Table 1
Summary of advantages and disadvantages of HLD and sterilization enhancements for reprocessing duodenoscopes
Method Advantages Disadvantages
Steam, sterilization • Rapidly microbicidal
• Least affected by organic or inorganic soils among
sterilization processes listed
• Rapid cycle time
• Deleterious for heat-sensitive instruments
• At present they cannot be used because current GI scopes
are not heat resistant
Hydrogen peroxide gas plasma,
sterilization
• Cycle time is ≥28 min, and no aeration necessary
• Used for heat- and moisture-sensitive items because
process temperature <50°C
• Compatible with most medical devices
• Endoscope or medical device restrictions based on lumen
internal diameter and length
• GI scopes cannot be processed
• No microbicidal efficacy data proving SAL 10-6 achieved
• Studies question microbicidal activity in presence of
organic matter and salt
• May damage endoscope
100% ETO, sterilization after
HLD, microbiologic
surveillance
• Single-dose cartridge and negative- pressure chamber
minimizes the potential for gas leak and ETO exposure
• Simple to operate and monitor
• Compatible with most medical materials
• Major endoscope manufacturer offers ETO as sterilization
option
• Ideally, ETO should be used after standard HLD
• Some data demonstrate reduced infection risk with HLD
followed by ETO
• Requires aeration time to remove ETO residue
• Only 20% of U.S. hospitals have ETO on-site
• Lengthy cycle and aeration time
• No microbicidal efficacy data proving SAL 10-6 achieved
• Studies question microbicidal activity in presence of
organic matter and salt
• ETO is toxic, a carcinogen, flammable
• May damage endoscope
Vaporized hydrogen peroxide,
sterilization
• Fast cycle time (55 min)
• Used for heat- and moisture-sensitive items (metal and
nonmetal devices)
• Endoscope or medical device restrictions based on lumen
internal diameter and length
• GI scopes cannot be processed
• No microbicidal efficacy data proving SAL 10−6 achieved
• No data demonstrating microbicidal activity in presence of
organic matter and salt
• May damage endoscope
HLD only (using FDA-cleared
HLD, such as OPA and glut)
• HLD inactivate MDR organisms, including CREs
• Current standard of care
• Wide availability
• Based on recent ERCP outbreaks, infection risk related to
device complexity and microbial load
• No enhancement to reduce infection risk associated with
ERCP scopes
• Some HLD (eg, aldehydes) may cross-link proteins
Double HLD (back-to-back);
microbiologic surveillance
• HLD inactivate MDR organisms, including CREs
• Wide availability
• A second HLD cycle may reduce or eliminate microbial
contaminants remaining from first cycle
• Based on recent ERCP outbreaks, infection risk related to
device complexity and microbial load
• Some HLD (eg, aldehydes) may cross-link proteins
Liquid chemical sterilant
processing system using




• HLD and chemical sterilant inactivate MDR organisms,
including CREs
• Offered as liquid chemical sterilant processing option
• Based on recent ERCP outbreaks, infection risk related to
device complexity and microbial load
• Not considered sterile because it is not a terminal
sterilization process and scope is rinsed with extensively
treated water
• Unclear if peracetic acid will penetrate crevices in elevator
channel and inactivate pathogens
HLD, microbiologic
surveillance
• HLD inactivate MDR organisms, including CREs
• Microbiologic surveillance offered as supplement by the
CDC
• Based on recent ERCP outbreaks, infection risk related to
device complexity and microbial load
• No data demonstrating reduced infection risk
• Sensitivity of microbiologic surveillance unknown
• 48-72 hours before culture results known
• No consensus regarding sampling scheme, 100% or 10% of
scopes per week or per month?
• No cutoff to define effective disinfection (0 GNR?)
HLD, ATP • HLD inactivate MDR organisms, including CREs
• Real-time monitoring tool
• Simple to conduct
• Detects organic residue
• Based on recent ERCP outbreaks, infection risk is related to
device complexity and microbial load
• No data demonstrating reduced infection risk
• Does not detect microbial contamination
• ATP not validated as risk factor for patient-to-patient
transmission
• Unknown cutoff level to assure safety
Abbreviations: ATP, adenosine triphosphate; CDC, Centers for Disease Control and Prevention; CRE, carbapenem-resistant Enterobacteriaceae; ERCP, endoscopic retrograde
cholangiopancreatography; ETO, ethylene oxide; FDA, Food and Drug Administration; GI, gastrointestinal; GNR, gram-negative rod; HLD, high-level disinfection;MDR, multidrug
resistant; OPA, ortho-phthalaldehyde; SAL, sterility assurance level.
hydrogen peroxide vapor, nitrogen dioxide,20 supercritical CO2, per-
acetic acid vapor, gaseous chlorine dioxide, steam sterilization for
heat-resistant GI endoscopes). These new technologies could greatly
improve the margin of safety and eliminate patient risk. ETO, which
was used by Epstein et al to terminate their outbreak,4 may be a
short-term solution for some hospitals, but it is not a long-term sat-
isfactory solution because many hospitals no longer have ETO, the
sterilization-aeration time is long (eg, 12-15 hours), and the process
may eventually damage the endoscopes. Additionally, there are no
studies in the peer-reviewed literature that demonstrate that we
can depend on ETO (or other LTST) to sterilize a duodenoscope fol-
lowing only the cleaning portion of the endoscope reprocessing
instructions (ie, brushing, flushing). In fact, Alfa et al found the ster-
ilization efficacy with 100% ETO or hydrogen peroxide gas plasma
was only 39.7% and 35%, respectively, when serum and salt load was
combined with a lumen carrier as the test challenge. When
penicylinders were inoculated with 7 organisms in the presence of
salt and serum sterilization efficacy with 100% ETO and hydrogen
peroxide gas plasma was 60.3% and 37%, respectively.21,22 For this
reason, if hospitals wish to consider ETO as an enhancement to their
current ERCP reprocessing, the scope should be cleaned and high-
level disinfected and dried per reprocessing instruction prior to ETO.
Prior cleaning and HLD reduces the microbial load and organic chal-
lenge that may interfere with the effectiveness of ETO sterilization.
It is unlikely, based on existing data that ETO (or other LTST) will
kill high numbers of pathogens in the presence of salt and serum
in a lumened device.
Table 1 provides the advantages and disadvantages for various
enhancements involving HLD or sterilization. Table 2 offers current
enhancements and future sterilization alternatives. Unfortunately,
many of these strategies may increase capital equipment and
reprocessing costs, cause changes in workflow and processes, and
cause a short-term shortage of duodenoscopes used in ERCP
procedures. For these reasons and others (including medical-
legal), we recommend the infection prevention clinician seek
executive-level support for the duodenoscope reprocessing en-
hancements needed tominimize the infection risk. Other alternative
solutions to avoid outbreaks associated with HLD of endoscopes
include the following: development of sterile disposable GI
endoscopes; improved GI endoscope design to reduce or elimi-
nate the challenges listed in Table 2; or a shift to other sterile
diagnostic modalities (eg, capsule endoscopy, blood tests to detect
GI cancer).
Improved prevention strategiesmust be urgently pursued. Despite
the very low risk of MDR infection after ERCP, any avoidable infec-
tion risk must be eliminated. Manufacturers (for endoscopes,
automated endoscope reprocessors, high-level disinfectants, and
LTST) and federal authorities (CDC, FDA, National Institutes of Health)
must be engaged by providing adequate resources to design and
complete the necessary studies for determining the risks posed by
current reprocessing of endoscopes and for developing new repro-
cessingmethods and practices. Infection prevention clinicians should
be encouraged to report and publish additional outbreaks related
to endoscopy, especially if current reprocessing methods were
adhered to; therefore, we can determine if the recent reports are
the tip-of-the-iceberg or an anomaly. Therefore, infection preven-
tion associated with ERCP and GI scopes is multifaceted, and no
single, immediately available strategy will eliminate this problem.
However, the immediate risks can be minimized by a multicom-
ponent strategy (eg, compliance with endoscope reprocessing
guidelines, HLD followed by ETO, periodic microbiologic sam-
pling). Unfortunately, most hospitals have not implemented
the reprocessing enhancements mentioned in Table 1, and
approximately one-third reported not using any surveillance
method to identify possible infections after duodenoscopy.23
Only when we implement new technologies (eg, equipment rede-
sign, single-use sterile endoscopes, sterilization of GI endoscopes
with technology that achieves an SAL of 10-6) will we eliminate the
risk of infection associated with duodenoscopes and other GI
endoscopes.
In May 2015, the FDA convened a panel to discuss recent reports
and epidemiologic investigations of the transmission of infections
associatedwith the use of duodenoscopes in ERCP procedures.24 After
presentations from industry, professional societies, and invited speak-
ers, the panelmade several recommendations to include reclassifying
duodenoscopes based on the Spaulding classification from
semicritical to critical to support the shift fromHLD to sterilization.25
Although the panel recommendations are nonbinding, they are used
to inform the FDA director, and they will likely result in guidance
or regulation for industry. In September 1992, the FDA recom-
mended that reusable dental handpieces and related instruments
be heat sterilized between each patient. This followed the first case
of dentist-to-patient transmission of HIV; however, this case was
not associated with a contaminated dental handpiece. We believe
Table 2
Challenges in high-level disinfection of GI endoscopes and preventive methods to
assure safety
Challenges in GI endoscope design for high-level disinfection
• Heat labile (ie, require low temperature disinfection)
• Heavily contaminated with use
• Complex
• Long, narrow lumens
• Sharp angles (eg, right angle bends)
• Occluded dead-end channels
• Difficult to clean and disinfect accessories (eg, elevator channel)
• Mated surfaces
• Springs and valves
• Rough or pitted surfaces
• Rapid turnover desired
• Damaged channels that impede microbial exposure to high-level
disinfectant
Steps in high-level disinfection (rigorously adhere to current standards for
cleaning and disinfection)
• Preclean at point of use
• Clean thoroughly




• Also assure competency of reprocessing staff (initial and at least annual
training assessment)
Possible current enhanced methods for reprocessing duodenoscopes currently
available
• Ethylene oxide sterilization after high-level disinfection with periodic
microbiologic surveillance
• Double high-level disinfection with periodic microbiologic surveillance
• High-level disinfection with scope quarantine until negative culture
• Liquid chemical sterilant processing system using peracetic acid (rinsed
with extensively treated potable water) with periodic microbiologic
surveillance
• Other FDA-cleared low-temperature sterilization technology (provided
material compatibility and sterilization validation testing performed using
the sterilizer and endoscope) after high-level disinfection, with periodic
microbiologic surveillance
• High-level disinfection with periodic microbiologic surveillance
Potential future methods to prevent GI endoscope-related outbreaks
• Steam sterilization GI endoscopes
• Optimize existing low temperature sterilization methods or develop
new low temperature sterilization methods proving SAL 10−6 achieved
(see text)
• Disposable sterile GI endoscopes
• Improved GI endoscope design (to reduce or eliminate challenges)
• Use of nonendoscope methods to diagnosis or treat disease (eg, capsule
endoscopy, blood tests to detect GI cancer, stool, DNA test)
Abbreviations: FDA, Food and Drug Administration; GI, gastrointestinal; SAL, stabil-
ity assurance level.
the FDA, in collaboration with industry and infection prevention cli-
nicians, should pursue new infection prevention strategies with
urgency and laser-like focus.
It was recommended at the meeting that this could be accom-
plished by shifting from HLD to sterilization and modifying the
Spaulding definition of critical items from “objects which enter sterile
tissue or the vascular system or through which blood flows should
be sterile” to “objects which directly or secondarily (ie, via a mucous
membrane, such as a duodenoscope) enter normally sterile tissue
of the vascular system of through which blood flows should be
sterile”.7,25 Implementation of these recommendations requires ster-
ilization technology that achieves an SAL of 10−6 of complex medical
instruments, such as duodenoscopes. Ideally, this shift would even-
tually involve not only endoscopes that secondarily enter normally
sterile tissue (eg, duodenoscopes, bronchoscopes) but also other
semicritical devices (eg, GI endoscopes).
Until these issues can be resolved, we should continue to provide
GI endoscopic (eg, ERCP) procedures, which are an important di-
agnostic and therapeutic modality. These procedures should be done
while strictly adhering to current endoscope reprocessing
guidelines3,4 with the enhancements offered (Tables 1 and 2) while
informing patients of the benefits (ie, potentially life-saving pro-
cedure) and risks.
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